More specifically, KRAS exon 2, exon 3 and exon 4 mutations are present in 13.98%, 1.17% and 0.62% of all cancer types [2,6], respectively, especially in pancreatic ductal adenocarcinoma (PDAC) (88% of patients), in colorectal cancer (CRC) (45–50% of cases) and in lung adenocarcinoma (AC) (30–35% of patients) (Table 1) [5,6,7,8]. This evidence concerns the gene KRAS and lung adenocarcinoma.